-
4μ8C: Practical IRE1α Inhibition Workflows
2026-09-04
Use 4μ8C as a pathway-dissection tool for separating IRE1α RNase activity from broader ER-stress toxicity in hypoxia and cancer models. This guide combines solvent handling, treatment design, orthogonal readouts, and troubleshooting for more reproducible unfolded protein response experiments.
-
Chloroquine Mechanisms in Cancer Therapy
2026-09-04
This 2024 review organizes the anticancer pharmacology of Chloroquine across autophagy-dependent and autophagy-independent mechanisms, emphasizing lysosomal, mitochondrial, apoptotic, and signaling effects. Its practical contribution is a framework for interpreting combination-treatment evidence while keeping toxicity, mechanistic ambiguity, and clinical translation in view.
-
One-step TUNEL Cy3 Kit for CRC Apoptosis
2026-09-03
Discover how the One-step TUNEL Cy3 Apoptosis Detection Kit can clarify DNA fragmentation in colorectal cancer models. This guide connects AKT1-directed pharmacology, translational tissue analysis, and rigorous apoptosis assay design.
-
Nitroaromatic Nannocystin Targets AKT1 in CRC
2026-09-03
The reference study identifies a synthetic nitroaromatic nannocystin that suppresses colorectal cancer models and shows in vivo activity in a patient-derived xenograft. Its integrated synthesis, organoid, animal, transcriptomic, docking, and cellular thermal shift analyses support AKT1 as a contributing molecular target while defining important limits for translation.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-02
The reference study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its experiments showed tumor-localized protein expression, restoration of p21-dependent cell-cycle control, and suppression of orthotopic tumor growth, while also defining important limitations for translation beyond preclinical models.
-
Making Epigenetic Plasticity Visible in HNSCC
2026-09-02
Metastatic head and neck squamous cell carcinoma is shaped by changing cellular identities, not fixed tumor subtypes. This thought-leadership article connects recent multi-omic findings on WDR54-driven plasticity with spatial protein and RNA imaging, showing how Cy5-based tyramide amplification can help translational teams test lineage transitions, detect scarce biomarkers, and design more decision-ready validation studies.
-
Chenodeoxycholic Acid: From FXR to Renal Protection
2026-09-01
Chenodeoxycholic Acid is more than a bile acid metabolism tool. By activating FXR, CDCA enables mechanism-led research spanning cholesterol homeostasis, nuclear receptor signaling, and the FXR–KLF11–JAK2/STAT3 axis in contrast-induced acute kidney injury.
-
EZ Cap™ OVA mRNA for Better Immune Models
2026-09-01
A translational framework for using Cap 1-capped Ovalbumin mRNA to separate antigen biology from delivery-driven inflammation, improve experimental consistency, and inform next-generation vaccine development research.
-
Fluorescein TSA Fluorescence System Kit for Astrocytes
2026-08-31
Translate astrocyte atlas discoveries into spatially resolved protein and RNA validation with localized tyramide signal amplification. This workflow is especially useful when conventional fluorescence cannot resolve low-abundance markers across developmental stages, brain regions, or species.
-
10058-F4 C-Myc-Max Dimerization Inhibitor
2026-08-31
10058-F4 is a small-molecule c-Myc-Max dimerization inhibitor that disrupts c-Myc/MAX-dependent transcription and supports mechanistic studies of apoptosis, acute myeloid leukemia, and prostate cancer models. Catalog data describe research-use formulations, while a 2024 human pluripotent stem-cell preprint links low-dose c-Myc:MAX inhibition to reduced TERT transcription and increased H3K27me3 at the TERT promoter.
-
Clozapine in Translational Schizophrenia Research
2026-08-30
A thought-leadership framework for using Clozapine to connect receptor pharmacology, ERK1/2 signaling activation, prefrontal-cortex biology, circuit modulation, and safety-oriented translational design in schizophrenia research.
-
Cheminformatics Design of Optimized Small-Molecule Libraries
2026-08-29
Moret et al. present a data-driven framework for evaluating and designing focused small-molecule libraries using target coverage, binding selectivity, cellular phenotypes, chemical structure, clinical-development status, and user priorities. The approach generated kinase and mechanism-of-action collections with improved coverage and reduced redundancy, providing a practical basis for more interpretable chemical-genetic experiments.
-
ABT-263 (Navitoclax) in Apoptosis Assays
2026-08-28
ABT-263 (Navitoclax) converts Bcl-2-family dependence into a measurable mitochondrial apoptosis phenotype, making it useful for cancer-cell sensitivity profiling, combination studies, and resistance analysis. This guide pairs practical apoptosis assay design with a motility-aware framework inspired by recent melanoma research.
-
20-HETE, TRPV1, and Itch in Chronic Dermatitis
2026-08-28
This study identifies a peripheral mechanism for allokinesis, in which normally painful capsaicin becomes itch-provoking in chronic dermatitis. By combining sensory-neuron manipulation, electrophysiology, metabolomics, and pharmacological inhibition, the authors connect elevated 20-HETE to TRPV1 activation in sensitized MrgprA3+ neurons.
-
Triterpene Prodrug for Targeted OSCC Chemotherapy
2026-08-27
This 2024 ACS Applied Materials & Interfaces study developed a carrier-free, self-assembled prodrug from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. Its central innovation is a thioketal-linked ROS-responsive design in which glycyrrhetinic acid helps amplify oxidative stress, promoting further drug release and synergistic tumor-cell apoptosis.